| HOME >> MEDICINE >> TECHNOLOGY |
6.2.1 Botulinum Toxin A 97
6.2.2 YM178 98
6.2.3 NX-1207 98
6.2.4 PRX302 99
6.2.5 NXL104/ceftazidime 100
7 Global Urological Disorders Market: Competitive Landscape 101
7.1 Market Share Analysis: Urological Disorders 101
7.2 Competitive Profiling 103
7.2.1 Astellas Pharma 103
7.2.2 Johnson and Johnson (J&J) 104
7.2.3 Pfizer 106
7.2.4 GlaxoSmithKilne (GSK) 107
7.2.5 Sanofi-Aventis 108
8 Global Urological Disorders Market: Strategic Consolidations 110
8.1 Overview 110
8.1.1 Warner Chilcott Acquires Prescription Drug Business of Procter & Gamble in October 2009 112
8.1.2 Actavis Group Acquires Floxapen from GlaxoSmithKline in May 2007 112
8.1.3 Biofusion Acquires Minority Stake in Muscagen in November 2006 112
8.1.4 Eli Lilly Reacquires Rights to Yentreve from Boehringer Ingelheim in February 2006 112
8.1.5 Odyssey Pharmaceuticals Sells SANCTURA to Esprit Pharma in May 2005 112
8.1.6 Ardana Bioscience Acquires Rights to Teverelix from AEterna Zentaris in April 2004 112
8.2 R&D Licensing Agreements 113
8.2.1 Deals by Indication 113
8.2.2 Deals by Phase 114
8.2.3 Deals by Geography 114
8.2.4 Deals by Licensing Type 115
8.2.5 Deals by Value ($) 115
8.2.6 Phase I 116
8.2.7 Phase II 117
8.2.8 Approved 118
9 Global Urological Disorders Market: Appendix 120
9.1 Market Definitions 120
9.2 Abbreviations 120
9.3 Research Methodology 121
9.3.1 Coverage 121
9.3.2 Secondary Research 121
9.3.3 Primary Research 122
9.3.4 Forecasts 122
9.3.5 Expert Panel Validation 124
9.4 Contact Us 125
9.5 Disclaimer 125
9.6 Sources 125
1.1 List of Tables
Table 1: Urological Disorders Market, Global, Sales Value ($bn), 2001–2009 13
Table 2: Urological
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |